Literature DB >> 12163327

Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach.

Jason Park1, Stephanie Schulz, Janis Haaf, John C Kairys, Scott A Waldman.   

Abstract

Guanylyl cyclase C (GC-C), a receptor specifically expressed in cells originating from differentiated intestinal epithelium, is a marker and therapeutic target for colorectal cancer metastases. Intestinal metaplasia, in which epithelial cells assume histological and molecular characteristics of differentiated intestinal enterocytes, is a common precursor to adenocarcinomas of the esophagus and stomach. Thus, those tumors, tissues adjacent to them, and their associated regional lymph nodes were assessed for GC-C expression by reverse transcription coupled with the PCR. GC-C mRNA was detected in five of five and eight of nine esophageal and gastric adenocarcinomas, respectively. Also, GC-C mRNA was detected in three of five and six of seven tissues adjacent to, but not histologically involved in, esophageal and gastric adenocarcinomas, respectively, reflecting molecular changes associated with neoplastic transformation preceding histopathological changes. In contrast, three normal gastric specimens did not express GC-C. Furthermore, GC-C mRNA was detected in 1 of 1 lymph node containing tumor cells by histopathology from a patient with gastric adenocarcinoma and in 3 of 11 lymph nodes, all of which were free of tumor cells by histopathology, from a patient with a gastroesophageal junction tumor. This is the first demonstration that GC-C is ectopically expressed by primary and metastatic adenocarcinomas of the esophagus and stomach and suggests that GC-C may be a sensitive and specific clinical marker and target for adenocarcinomas of the upper gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163327

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  16 in total

Review 1.  E. coli heat-stable enterotoxin and guanylyl cyclase C: new functions and unsuspected actions.

Authors:  Ralph A Giannella; Elizabeth A Mann
Journal:  Trans Am Clin Climatol Assoc       Date:  2003

2.  Bile acids initiate lineage-addicted gastroesophageal tumorigenesis by suppressing the EGF receptor-AKT axis.

Authors:  Li Gong; Philip R Debruyne; Matthew Witek; Karl Nielsen; Adam Snook; Jieru E Lin; Alessandro Bombonati; Juan Palazzo; Stephanie Schulz; Scott A Waldman
Journal:  Clin Transl Sci       Date:  2009-08       Impact factor: 4.689

Review 3.  GUCY2C molecular staging personalizes colorectal cancer patient management.

Authors:  Jian P Gong; Stephanie Schulz; Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

4.  A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.

Authors:  Khaldoun Almhanna; David Wright; Teresa Macarulla Mercade; Jean-Luc Van Laethem; Antonio Cubillo Gracian; Carmen Guillen-Ponce; Jason Faris; Carolina Muriel Lopez; Richard A Hubner; Johanna Bendell; Alain Bols; Jaime Feliu; Naureen Starling; Peter Enzinger; Devalingham Mahalingham; Wells Messersmith; Huyuan Yang; Adedigbo Fasanmade; Hadi Danaee; Thea Kalebic
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

5.  Ectopic expression of guanylyl cyclase C and endogenous ligand guanylin correlates significantly with Helicobacter pylori infection in gastric carcinogenesis.

Authors:  Jian-Feng Zhang; Zhen-Biao Mao; Zeng-Li Li; Shi-Min Xue; Hui-Jun Zhu; Hong Zhang; Run-Zhou Ni
Journal:  Med Oncol       Date:  2011-10-05       Impact factor: 3.064

6.  Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.

Authors:  Matthew Witek; Erik S Blomain; Michael S Magee; Bo Xiang; Scott A Waldman; Adam E Snook
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-01       Impact factor: 7.038

7.  Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models.

Authors:  Anna R Schreiber; Anna Nguyen; Stacey M Bagby; John J Arcaroli; Betelehem W Yacob; Kevin Quackenbush; Joe L Guy; Thomas Crowell; Bradley Stringer; Hadi Danaee; Thea Kalebic; Wells A Messersmith; Todd M Pitts
Journal:  Clin Cancer Drugs       Date:  2018

Review 8.  Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.

Authors:  Ariana A Entezari; Adam E Snook; Scott A Waldman
Journal:  Expert Opin Ther Targets       Date:  2021-06-15       Impact factor: 6.797

9.  Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.

Authors:  John C Flickinger; Jeffrey A Rappaport; Joshua R Barton; Trevor R Baybutt; Amanda M Pattison; Adam E Snook; Scott A Waldman
Journal:  Biomark Med       Date:  2021-01-20       Impact factor: 2.851

Review 10.  Current understanding of guanylin peptides actions.

Authors:  Aleksandra Sindic
Journal:  ISRN Nephrol       Date:  2013-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.